Pat  Cotroneo net worth and biography

Pat Cotroneo Biography and Net Worth

CFO of FibroGen
Pat Cotroneo serves as Chief Financial Officer of the Company. Mr. Cotroneo joined us in 2000 as Controller, was promoted to Vice President of Finance, and subsequently promoted to Chief Financial Officer in 2008. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. Prior to SyStemix, he was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a Bachelor of Science degree with honors from the University of San Francisco and was selected a Louise M. Davies scholar.

What is Pat Cotroneo's net worth?

The estimated net worth of Pat Cotroneo is at least $600,389.09 as of June 15th, 2021. Mr. Cotroneo owns 276,677 shares of FibroGen stock worth more than $600,389 as of March 19th. This net worth evaluation does not reflect any other assets that Mr. Cotroneo may own. Learn More about Pat Cotroneo's net worth.

How do I contact Pat Cotroneo?

The corporate mailing address for Mr. Cotroneo and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Pat Cotroneo's contact information.

Has Pat Cotroneo been buying or selling shares of FibroGen?

Pat Cotroneo has not been actively trading shares of FibroGen during the last quarter. Most recently, Pat Cotroneo sold 4,053 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $25.62, for a transaction totalling $103,837.86. Following the completion of the sale, the chief financial officer now directly owns 276,677 shares of the company's stock, valued at $7,088,464.74. Learn More on Pat Cotroneo's trading history.

Who are FibroGen's active insiders?

FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.

Are insiders buying or selling shares of FibroGen?

In the last year, FibroGen insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $95,500.00. In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 63,716 shares worth more than $1,014,059.35. The most recent insider tranaction occured on March, 7th when CEO Thane Wettig bought 50,000 shares worth more than $95,500.00. Insiders at FibroGen own 2.4% of the company. Learn More about insider trades at FibroGen.

Information on this page was last updated on 3/7/2024.

Pat Cotroneo Insider Trading History at FibroGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2021Sell4,053$25.62$103,837.86276,677View SEC Filing Icon  
12/15/2020Sell3,068$43.60$133,764.80266,144View SEC Filing Icon  
9/15/2020Sell3,070$43.63$133,944.10272,226View SEC Filing Icon  
9/3/2020Sell15,004$50.91$763,853.64278,947View SEC Filing Icon  
6/16/2020Sell3,928$39.68$155,863.04271,060View SEC Filing Icon  
3/16/2020Sell9,239$26.36$243,540.04245,705View SEC Filing Icon  
9/17/2019Sell3,201$41.38$132,457.38244,432View SEC Filing Icon  
6/18/2019Sell3,201$43.12$138,027.12250,777View SEC Filing Icon  
3/19/2019Sell7,665$55.41$424,717.65239,504View SEC Filing Icon  
2/28/2019Sell14,787$60.08$888,402.96267,891View SEC Filing Icon  
12/18/2018Sell3,330$41.10$136,863.00222,004View SEC Filing Icon  
9/13/2018Sell2,318$59.50$137,921.00230,922View SEC Filing Icon  
9/10/2018Sell1,011$57.35$57,980.85220,422View SEC Filing Icon  
6/14/2018Sell10,069$59.47$598,803.43224,704View SEC Filing Icon  
6/8/2018Sell1,011$55.55$56,161.05228,034View SEC Filing Icon  
6/4/2018Sell6,013$55.16$331,677.08230,311View SEC Filing Icon  
5/21/2018Sell14,987$55.04$824,884.48View SEC Filing Icon  
3/15/2018Sell42,026$52.85$2,221,074.10168,334View SEC Filing Icon  
3/13/2018Sell5,932$54.61$323,946.52168,334View SEC Filing Icon  
3/8/2018Sell1,894$53.12$100,609.28176,160View SEC Filing Icon  
2/16/2018Sell49,500$55.96$2,770,020.00207,392View SEC Filing Icon  
1/22/2018Sell25,000$48.72$1,218,000.00208,852View SEC Filing Icon  
12/11/2017Sell2,851$46.00$131,146.00183,852View SEC Filing Icon  
9/11/2017Sell2,851$49.45$140,981.95157,405View SEC Filing Icon  
8/8/2017Sell95,000$50.61$4,807,950.00173,366View SEC Filing Icon  
8/2/2017Sell28,346$33.97$962,913.62170,666View SEC Filing Icon  
7/6/2017Sell4,000$34.00$136,000.00167,366View SEC Filing Icon  
6/22/2017Sell3,000$32.00$96,000.00166,366View SEC Filing Icon  
6/19/2017Sell5,500$30.00$165,000.00168,866View SEC Filing Icon  
6/12/2017Sell2,891$28.75$83,116.25163,366View SEC Filing Icon  
4/25/2017Sell6,500$28.00$182,000.00164,405View SEC Filing Icon  
1/11/2017Sell6,500$24.00$156,000.00138,748View SEC Filing Icon  
12/12/2016Sell2,344$22.05$51,685.20132,248View SEC Filing Icon  
9/12/2016Sell2,345$18.22$42,725.90134,359View SEC Filing Icon  
6/15/2016Sell1,796$16.49$29,616.04138,114View SEC Filing Icon  
5/16/2016Sell6,107$17.60$107,483.20141,868View SEC Filing Icon  
11/25/2015Sell5,000$30.00$150,000.00107,775View SEC Filing Icon  
9/15/2015Sell1,093$27.95$30,549.35107,498View SEC Filing Icon  
9/10/2015Sell7,500$27.33$204,975.00107,251View SEC Filing Icon  
7/20/2015Sell7,881$23.47$184,967.07View SEC Filing Icon  
See Full Table

Pat Cotroneo Buying and Selling Activity at FibroGen

This chart shows Pat Cotroneo's buying and selling at FibroGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

FibroGen Company Overview

FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $2.17
Low: $1.95
High: $2.36

50 Day Range

MA: $1.69
Low: $0.75
High: $2.73

2 Week Range

Now: $2.17
Low: $0.33
High: $20.90

Volume

2,554,005 shs

Average Volume

2,808,177 shs

Market Capitalization

$214.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66